Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Jack Cuzick(Queen Mary University of London), Ivana Šestak(Queen Mary University of London), Bernardo Bonanni(European Institute of Oncology), Joseph P. Costantino(NSABP Foundation), Steve Cummings(California Pacific Medical Center), Andrea DeCensi(Ente Ospedaliero Ospedali Galliera), Mitch Dowsett(Royal Marsden Hospital), John Forbes(Calvary Mater Newcastle Hospital), Leslie G. Ford(National Cancer Institute), Andrea Z. LaCroix(Fred Hutch Cancer Center), John L. Mershon(Abbott Fund), Bruce Mitlak(Eli Lilly (United States)), Trevor J. Powles(Institute of Cancer Research), Umberto Veronesi(European Institute of Oncology), Victor G. Vogel(UPMC Hillman Cancer Center), D. Lawrence Wickerham(University of Pittsburgh)
Cited by 485Open Access
Abstract
Related Papers
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham et al.|JNCI Journal of the National Cancer Institute|1998|5.5k
Tamoxifen for early breast cancer: an overview of the randomised trials
Early Breast Cancer Tr.group, -, Klijn, Jan|The Lancet|1998|4.1k